fremanezumab Ajovy
Selected indexed studies
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. (JAMA, 2018) [PMID:29800211]
- Fremanezumab for the Preventive Treatment of Chronic Migraine. (N Engl J Med, 2017) [PMID:29171818]
- Fremanezumab. (, 2006) [PMID:30371997]
_Worker-drafted node — pending editorial review._
Connections
fremanezumab Ajovy is a side effect of
Sources
- Migraine overview and summary of current and emerging treatment options. (2019) pubmed
- Fremanezumab. (2006) pubmed
- Fremanezumab for the Preventive Treatment of Chronic Migraine. (2017) pubmed
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. (2018) pubmed
- Fremanezumab: Pediatric First Approval. (2025) pubmed
- Fremanezumab in Children and Adolescents with Episodic Migraine. (2026) pubmed
- Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder: The UNITE Randomized Clinical Trial. (2025) pubmed
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. (2019) pubmed
- Fremanezumab: First Global Approval. (2018) pubmed
- CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention. (2024) pubmed